Healthcare
KalVista Pharmaceuticals, Inc.(KALV)
Live Price
Offline$27.00
+0.00% today
1Y Change
+131.16%
Window
Jun 25, 2025 โ Jun 12, 2026
- Market Cap
- $1.37B
- Revenue Growth
- 0.0%
- EPS Growth
- -7.3%
- Dividend Yield
- 0.0%
Coverage: 243 bars ยท Jun 25, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
KalVista Pharmaceuticals, Inc. (KALV) is a Healthcare stock with a market cap of $1.37B and listed on NASDAQ. The stock last traded around $27.00 and up 131.2% across the available one-year price window (Jun 25, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -7.3%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -7.3%, free cash flow -71.0% with operating margin -231.1% and ROIC -57.9%. Valuation already assumes a fairly strong business story at price/sales 18.2. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines KALV price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
-231.1% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 5, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -7.3%, with operating margin around -231.1%.
The next real check-in already has a date
The next earnings event is scheduled for Sep 3, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +19.6% over the next 5 trading days and finished higher after 3 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 5, 2026 | โ | +0.0% | +0.1% | +0.9% |
2026 Mar 24, 2026 | -87.0% | +4.1% | +22.3% | +18.8% |
2025 Nov 10, 2025 | +4.2% | +5.3% | +36.5% | +48.4% |
Benchmark Edge
KALV vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
KALV
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
KALV Max Drawdown
-32.79%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for KALV and SPY.
Company Overview
KalVista Pharmaceuticals, Inc.
NASDAQ Global Market
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.
- Leadership
- Benjamin L. Palleiko
- IPO Date
- Apr 9, 2015
- Employees
- 150
- Street Address
- 55 Cambridge Parkway
- Mailing
- Cambridge, MA, 02142
- Region
- Cambridge, MA, US
- Reporting Currency
- USD
- Investor Line
- 857 999 0075
- Last Updated
- May 1, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 18.2
- Price/Book
- โ
Growth
- Revenue
- 0.0%
- EPS
- -7.3%
- Free Cash Flow
- -71.0%
Profitability
- Gross Margin
- 68.7%
- Operating Margin
- -231.1%
- Net Margin
- -222.8%
- ROE
- -444.4%
- ROIC
- -57.9%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 5.58
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.